30 Aug

FDA Grants Eden Spine 510(K) Clearance for Its Thoraco Lumbar Spine Locking Plate – SPHYNX™

The SPHYNX™ is the ideal complement to Eden Spine proprietary, expandable titanium vertebral body replacement implant with rotatable endplates, the GIZA™ which provides multiple angulation options by simple endplates rotation. The GIZA™ is intended to replace and fuse a collapsed, damaged, or unstable vertebral body due to a tumor or a fracture.

Made of titanium, the low profile SPHYNX™ is to be implanted via the antero-lateral approach for the treatment of thoraco-lumbar instabilities. Indications include spinal fractures, vertebral tumors, secondary instabilities of the thoracic and thoraco-lumbar spine, and any other indication requiring an anterior stabilization low profile.

“The SPHYNX™ is the latest innovation coming from our R&D department in Geneva, Switzerland,” says Ben Mokhtar, President of Eden Spine Europe, SA. “Our goal was to develop a technology that was simple to use, intuitive, and worked with the anatomy. To achieve that goal we have developed a cutting edge integrated locking system, minimized the thickness of the implant in an effort to respect the surrounding tissues, and maximized the range of precurved plates, to provide optimal adaptation to patient’s anatomy.” The SPHYNX™ was granted CE Mark approval in 2016. ------- About Eden Spine Europe SA:  Eden Spine is a privately held, technology driven spinal organization based in Switzerland since 2005. The company distributes a range of innovative spinal technologies in the United States and abroad. Eden Spine patented portfolio is composed of a mix of fusion and non-fusion technologies.

For distribution opportunities, please contact us at Customer.service(at)edenspine(dot)com or visit http://www.edenspine.com

Read More
30 Aug

K2M Group Holdings, Inc. Announces Definitive Agreement To Be Acquired by Stryker Corporation

LEESBURG, Va., Aug. 30, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance, today announced a definitive merger agreement with Stryker Corporation ("Stryker", NYSE:SYK) pursuant to which Stryker has agreed to acquire all of the issued and outstanding shares of common stock of K2M in an all cash transaction for $27.50 per share, or a total equity value of approximately $1.4 billion. The purchase price represents a 27% premium over K2M's average closing price during the 90 trading days ended August 29, 2018. Upon completion of the proposed transaction, K2M will become a wholly owned subsidiary of Stryker Corporation. Post-closing, K2M's Chairman, Chief Executive Officer, and President Eric D. Major is expected to be appointed as the President of Stryker's Spine division. "Joining Stryker will be a very exciting next chapter for our global team and surgeon customers around the world," said Chairman, Chief Executive Officer, and President of K2M, Eric D. Major. "Stryker's established leadership in the orthopedic and neurosurgical market, combined with K2M's culture of innovation and leadership in complex spine and minimally invasive solutions, represent a powerful opportunity for Stryker to strengthen its leadership in the $10 billion global spine market". "This acquisition underscores our commitment to the spinal market, which is the largest segment of Orthopaedics with significant unmet needs," stated Kevin A. Lobo, Chairman and Chief Executive Officer, Stryker. "We believe K2M will significantly enhance our presence with surgeons, patients and employees in both the spine and related neurotechnology markets." The proposed transaction is expected to close late in the fourth quarter of 2018, subject to customary closing conditions, including approval by K2M's stockholders and the receipt of certain regulatory approvals. The proposed transaction has been approved by the Board of Directors of both companies and is not subject to any financing condition. In connection with this transaction, Piper Jaffray & Co. is acting as financial advisor and Simpson Thacher & Bartlett LLP is acting as legal advisor to K2M. About K2M Group Holdings, Inc. K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company's technologies, techniques and leadership in the 3D-printing of spinal devices, enables K2M to compete favorably in the global spine surgery market. For more information, visit www.K2M.com and connect with us on FacebookTwitterInstagramLinkedIn and YouTube. About Stryker Corporation Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com. Forward-Looking Statements The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements.  These forward-looking statements include statements relating to the expected timing, completion and effects of the proposed merger, as well as other statements representing management's beliefs about, future events, transactions, strategies, operations and financial results, including, without limitation, our expectations with respect to the costs and other anticipated financial impacts of the merger; future financial and operating results of K2M Group Holdings, Inc. ("K2M"); K2M's plans, objectives, expectations and intentions with respect to future operations and services; required approvals to complete the merger by our stockholders and by governmental regulatory authorities, and the timing and conditions for such approvals; the stock price of K2M prior to the consummation of the transactions; and the satisfaction of the closing conditions to the proposed merger.  Such forward-looking statements often contain words such as "assume," "will," "anticipate," "believe," "predict," "project," "potential," "contemplate," "plan," "forecast," "estimate," "expect," "intend," "is targeting," "may," "should," "would," "could," "goal," "seek," "hope," "aim," "continue" and other similar words or expressions or the negative thereof or other variations thereon.  Forward-looking statements are made based upon management's current expectations and beliefs and are not guarantees of future performance.  Such forward-looking statements involve numerous assumptions, risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any such statements.  Our actual business, financial condition or results of operations may differ materially from those suggested by forward-looking statements as a result of risks and uncertainties which include, among others, those risks and uncertainties described in any of our filings with the Securities and Exchange Commission (the "SEC").  Certain other factors which may impact our business, financial condition or results of operations or which may cause actual results to differ from such forward-looking statements are discussed or included in our periodic reports filed with the SEC and are available on our website at www.k2m.com under "Investor Relations." You are urged to carefully consider all such factors.  Although it is believed that the expectations reflected in such forward-looking statements are reasonable and are expressed in good faith, such expectations may not prove to be correct and persons reading this communication are therefore cautioned not to place undue reliance on these forward-looking statements which speak only to expectations as of the date of this communication.  We do not undertake or plan to update or revise forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections, or other circumstances occurring after the date of this communication, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized.  If we make any future public statements or disclosures which modify or impact any of the forward-looking statements contained in or accompanying this communication, such statements or disclosures will be deemed to modify or supersede such statements in this communication. Additional Information and Where to Find It This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval.  This communication relates to a proposed acquisition of K2M by Stryker Corporation.  In connection with this proposed acquisition, K2M may file one or more proxy statements or other documents with the SEC.  This communication is not a substitute for any proxy statement or other document K2M may file with the SEC in connection with the proposed transaction.  INVESTORS AND SECURITY HOLDERS OF K2M ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.  Any definitive proxy statement(s) (if and when available) will be mailed to stockholders of K2M.  Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by K2M through the website maintained by the SEC at http://www.sec.gov.  Copies of the documents filed with the SEC by K2M will be available free of charge on K2M's internet website at www.k2m.com or upon written request to: Secretary, K2M Group Holdings, Inc., 600 Hope Parkway, SE, Leesburg, Virginia 20175, or by telephone at (703) 777-3155. Participants in Solicitation K2M, its directors and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction.  Information regarding the persons who may, under the rules of the SEC, be deemed participants in such solicitation in connection with the proposed merger will be set forth in the proxy statement if and when it is filed with the SEC.  Information about the directors and executive officers of K2M is set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on March 1, 2018, its proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on April 20, 2018, its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2018 and June 30, 2018, which were filed with the SEC on May 2, 2018 and August 2, 2018, respectively, and its Current Reports on Form 8-K or Form 8-K/A, which were filed with the SEC on January 8, 2018, January 9, 2018, February 28, 2018, March 29, 2018, May 1, 2018, June 11, 2018, June 14, 2018, June 18, 2018 and August 1, 2018. These documents can be obtained free of charge from the sources indicated above.  Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available.

Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.Mike Piccinino, CFA
443-213-0500
K2M@westwicke.com

Read More
29 Aug

Sports Medicine Market USD 9,655.6 Mn Revenue Expected by 2023 | Increasing Awareness on Sports Injury to Drive Bright Future

Pune, India, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Market Research Future® has recently published its Premium Report on Global Sports Medicine Market which reveals that the sports medicine market is projected to grow at a promising CAGR of 8.9% during the forecast period of 2017 to 2023. Sports medicine is a necessary part of the sports and athletics sector due to its use in ensuring sportspeople and athletes are in the right physical condition to perform. The global sports medicine market is expected to reach an estimated USD 9,655.6 Mn by the end of 2023. Global and regional sporting & athletic events have become highly commonplace with thousands of individuals participating in some capacity or the other. Recreational sports are often part of most curriculums in schools where participation is highly encouraged. Injuries in the line of extensive physical activities are inevitable. The global population is at an all-time high, and as such, growing incidences of sports injuries have been recorded which has increased the demand for sports medicine. Moreover, in response to rising sports-related injuries, there has been a noticeable increase in the number of sports medicine associations, thus driving market growth. Increasing awareness with regards to sports medicine as a niche part of the healthcare sector and rapid technological advancements in the healthcare sector is expected to be some other important drivers of the market. High costs associated with sports medicine and unfavorable reimbursement policies are expected to hinder market growth. Lack of skilled professionals in sports medicine for the treatment of pediatric sports injuries is expected to pose a challenge to market growth. However, with growing awareness, the market represents untapped opportunities which are likely to expand the market, particularly in pediatric sports medicine in the coming years. Get Exclusive Sample Report of Sports Medicine Market Report Enabled with Top 10 Players Geographical Overview and Respective Tables and Figures at https://www.marketresearchfuture.com/sample_request/3503 Key Players Overview Mentioned MRFR has analyzed the competitive landscape of the global sports medicine market to reveal the various strategies employed by leading market players. Spreading awareness, the establishment of new sports medicine centers, and investments in research & development are some of the market strategies prominent players employ. Market players of note that have been included in the report are Smith & Nephew, Stryker, Medtronic, Zimmer Biomet, CONMED Corporation, Arthrex Inc., GE Healthcare, DePuy Synthes, and others. Latest Industry News

  • The U.S based BWHealth, a sports injury prevention and treatment organization has received investments of USD 600,000 toward the scaling of its newest line of injury prevention products.
  • Stryker has acquired MITA LLC, a startup set up with the intention to offer a post free hip distraction system. The novel system carries great potential in sports medicine market.
Market Segmentation MRFR's segmental analysis has been performed on the basis of product, application, procedure, end-user, and region. By product, the Sports Medicine Market is segmented to include joint reconstructive & repair products, accessories & consumables, support & recovery products and others. The joint reconstructive & repair products segment has been sub-segmented into ligament repair devices, implants, fracture, prosthetic devices, arthroscopy devices, and others. The support and recovery products segment has been further divided to include topical pain relief products, monitoring devices, thermal therapy devices, braces & support, monitoring devices, and others. By application, the market is divided into spine treatment, hip treatment, knee treatment, shoulder treatment, and others. By procedure, the market is categorized into tendon to bone, cartilage repair, and tendinosis. The tendinosis segment accounts for over half of the total market share. Tendinosis is chronic in nature and afflicts tendons which experience continuous stress over time which is highly common is sportspeople and athletes who carry the same sporting activities for years on end. By end user, the market is segmented into ambulatory care, trauma centers, hospitals & emergency care and others. Globally, the market has been segmented region-wise into North America, Europe, Asia Pacific and the Middle East & Africa. High Number of Sports Medicine Centers Boost North America to Leading Position North America, with its inclusion of the U.S, accounts for a market share of 39%, thus making it the most significant region in the global sports medicine market. Sports and athletics possess high importance in this region with sports like football and baseball being highly popular. Physical education and athletics are encouraged from a young age and children often participate in various sporting activities. As a result, there is an increasing number of sports medical centers being established in the region to treat the rising occurrences of sports injuries thus augmenting market growth. Meanwhile, the Asia Pacific is growing at the highest CAGR of 9.2% during the assessment period. The regions healthcare sector is witnessing swift growth, and awareness regarding sports injury and the growing importance of physical education has provided the sports medicine market with opportunities for growth. Get Discount on Sports Medicine Market Report at https://www.marketresearchfuture.com/check-discount/3503 Related Reports North America Sports Medicine & Therapies Market-Forecast to 2023 North America Sports Medicine & Therapies Market Research Report, By Product (Helping Fractures Heal, Surgical Devices, Arthroscopy Devices, Orthopaedic Braces), By Area Of Application (Spine, Foot And Knee, Hip, Shoulder And Elbow, Other), By Procedure (Tendinosis, Tendon To Bone, Cartilage Repair), By End User (Hospitals & Emergency Care, Trauma Centres, Ambulatory Care)- Forecast To 2023 Global Precision Medicine Market Research Report – Forecast to 2022 Global Precision Medicine Market Information, By Ecosystem (pharma & biotech companies, diagnostic tool companies, healthcare IT/ big data companies, clinical laboratories), By Sub-markets (companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics, molecular diagnostics, others), By Therapeutics (cancer/oncology, cardiovascular disease, central nervous system, infectious diseases, others) - Forecast to 2022

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Read More
29 Aug

SeaSpine to Participate in the 13th Annual Wells Fargo Securities Healthcare Conference (corrected time)

CARLSBAD, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the Company plans to participate in the 13th Annual Wells Fargo Securities Healthcare Conference at the Westin Copley Place in Boston, Massachusetts on Wednesday, September 5th, 2018 at 9:05 am ET. A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.seaspine.com. A replay will remain available on the website for 30 days after the webcast. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete procedural solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Investor Relations Contact Lynn Pieper (415) 937-5402 ir@seaspine.com

Read More
29 Aug

Globus Medical to Exhibit Latest Advancements in MIS Spine Surgery at SMISS Annual Forum

AUDUBON, Pa., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will feature its ExcelsiusGPS® revolutionary robotic guidance and navigation system along with its latest advancements in expandable interbody technology at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum being held September 6-8, 2018, in Las Vegas, Nevada. As part of the Forum’s scientific agenda, two clinical studies will be presented highlighting Globus Medical’s expandable lateral interbody spacer technology designed to restore disc height, increase lordosis, and reduce subsidence compared to traditional static spacers. The company will also host an ExcelsiusGPS® workshop presented by Dr. Sabino D’Agostino, a neurosurgeon from South Carolina, who will discuss his transition to the ExcelsiusGPS® platform and the impact it has had on his minimally invasive spine surgery procedures. “As leaders in the musculoskeletal device industry, we are committed to supporting research, education, and development of medical advancements through minimally invasive spine surgery,” said Andrew Iott, Senior Vice President, Global Product Development. “We are proud to be a sponsor of SMISS and are excited to showcase our state-of-the-art ExcelsiusGPS® robotic system and best-in-class platform of innovative expandable implants for MIS spine surgery.” Globus welcomes SMISS attendees to clinical presentations and workshops on Friday, September 7.

7:30am: Pompeian III/IV ExcelsiusGPS® First Clinical Experience Sabino D’Agostino, MD; Charleston Brain and Spine, Charleston, SC 11:05am: Florentine Ballroom A Clinical Study to Evaluate Static versus Expandable Lateral Lumbar Interbody Fusion Devices: With One-year Follow-up  Richard Frisch, MD; Southeastern Spine Institute, Mount Pleasant, SC 11:17am: Florentine Ballroom Do Expandable Cages Lead to a Higher Incidence of Subsidence? Two-year Follow-up of Lateral Lumbar Interbody Fusions Dan Cohen, MD; Spine Care Institute of Miami Beach, Miami Beach, FL
Globus Medical invites meeting attendees to Booth# 201 to experience its most recent product innovations and discuss MIS advancements. About Globus Medical, Inc. Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com. Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. Contact: Brian Kearns Vice President, Business Development and Investor Relations Phone: (610) 930-1800 Email:  investors@globusmedical.com www.globusmedical.com

Read More
28 Aug

Nanovis Announces Successful Completion of $5.5 Million Investment Round To Fund Technology-Driven Growth

Nanovis, an innovative and fast-growing technology company selling nano-technology enhanced spinal implants, announced today the successful completion of a $5.5 million funding round managed by Commenda Securities. Key investors include Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital, and Ellipsis Ventures.

“Our investment in Nanovis is consistent with our mission to support the ongoing development and success of entrepreneurial businesses across Indiana. This latest round of funding will provide Nanovis the growth capital they need as a high-performing, high-growth business,” says Elevate Ventures CEO Chris LaMothe.

Nanovis will use the funds to meet increased working capital and sales needs from surging demand from surgeons and distributors for Nanovis’ nanotechnology enhanced spinal implants.

“Investors recognized that Nanovis’ technology portfolio offers interbodies with the best combination of a deeply porous bone interface scaffold with a tailored nanotube surface and bridging bone visualization. Nanovis’ nanotube surface is the only nanotechnology in the spine market with which scientists can customize and control the spacing of the nanofeatures,” says Nanovis CEO Matt Hedrick. “Appropriate nanofeature design and control is important in optimizing bone growth. As a result, our distribution partners are already seeing rapid sales growth and hospital approvals for Nanovis' FortiCore interbodies. In addition, we are receiving strong interest from surgeons in participating in our nanotube enhanced FortiCore interbody launch.”

Nanovis invents, acquires, and commercializes technologies that offer meaningfully superior implants to reduce fixation and infection related complications. Surgeons seeking for the best outcomes for their patients by utilizing the leading-edge nanotechnology, now have the option with Nanovis implants.

Nanovis’ nanotube enhanced FortiCore interbodies have deeply porous interconnected titanium scaffolds enhanced with a carefully designed nanotube surface and intermolded with a PEEK core, giving surgeons the most advanced interbody fixation technology with very good bridging bone imaging.

For more information about how to help patients, or better serve surgeons with Nanovis’ nanotechnologies, please visit us during the North American Spine Society (NASS) 2018 meeting September 26-29 in Los Angeles at Booth #2260 or call 1-317-507-1058.

For more information about distribution opportunities, please contact Jeff Shepherd, Vice President of Sales, at jeff.shepherd@nanovistechnology.com.

About Elevate Ventures Elevate Ventures is a private venture development organization that nurtures and develops emerging and existing high-growth businesses into high-performing, Indiana-based companies. Elevate Ventures accomplishes this by providing access to capital, rigorous business analysis and robust advisory services that connect companies with the right mix of resources businesses need to succeed long-term. Learn more about Elevate Ventures at http://www.elevateventures.com.

About 1st Source Capital Corp. The venture capital arm of South Bend, IN-based 1st Source Bank, invests in growing companies that have the ability to impact our local communities. The Bank’s parent company, 1st Source Corporation, has assets of $5.2 billion and is the largest locally controlled financial institution in the northern Indiana-southwestern Michigan area. For more information, visit http://www.1stsource.com.

About Nanovis Nanovis’ mission is to develop science-enhanced, life-improving technologies targeted at tissue fixation and infection. The Company maintains a technology portfolio intended to fuel 10 years of growth. Focused on aggressive, sustainable growth in the Spine market, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCore® line of interbody fusion devices; an advanced nanotube-surface technology; and surface technologies with anti-colonization and bactericidal capabilities.

Read More
28 Aug

Wright Medical Group N.V. Announces Pricing of Public Offering of Ordinary Shares

AMSTERDAM, The Netherlands, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) today announced the pricing of its previously announced registered underwritten public offering of 18,248,932 of its ordinary shares at an initial price to the public of $24.60 per share.  The net proceeds to Wright from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $423 million.  The offering is expected to close on or about August 30, 2018, subject to customary closing conditions.  J.P. Morgan is acting as sole underwriter for the offering. Wright intends to use the net proceeds of the offering to fund the purchase price of the previously announced pending acquisition (Acquisition) of Cartiva, Inc., as well as costs and expenses related thereto.  The offering is not contingent on the closing of the Acquisition.  If for any reason the Acquisition does not close, Wright intends to use the net proceeds of the offering for general corporate purposes. An automatic shelf registration statement relating to the ordinary shares offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on May 4, 2016 and was effective upon filing. The securities may be offered only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on its website.  When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Wright Medical Group N.V. Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide.  Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding our expectations related to the offering discussed in this press release. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations. Applicable risks and uncertainties include, among others, the inability of the company to complete the anticipated sale of equity securities or the acquisition of Cartiva, Inc., or a delay in closing of the same.  These and other risks are described under the caption “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 31, 2017, filed by Wright with the SEC on February 28, 2018, and subsequent SEC filings by Wright, including, without limitation, its Quarterly Reports on Form 10-Q for the quarters ended April 1, 2018 and July 1, 2018. Investors should not place undue reliance on the forward-looking statements contained in this release. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Investors & Media: Julie D. Dewey Sr. Vice President, Chief Communications Officer Wright Medical Group N.V. (901) 290-5817 julie.dewey@wright.com

Read More
28 Aug

Ceterix Orthopaedics Announces FDA Clearance of New Suture Cartridge, Providing Increased Flexibility and Enhanced Options for Surgeons

August 28, 2018

FREMONT, Calif.--(BUSINESS WIRE)--Ceterix® Orthopaedics, Inc., a leader in the development of cutting-edge surgical tools for orthopaedic surgeons, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an added feature to the NovoStitch® Pro Meniscal Repair System – a size 0 suture cartridge – offering surgeons more options to repair meniscal tears. The NovoStitch Pro system enables surgeons to place stitches arthroscopically in tight joint compartments, allowing them to address meniscal tears which have not been amenable to repair in the past. With the addition of the NovoStitch Pro’s new 0 suture cartridge, surgeons have expanded options in suture size and are able to pass a complete stitch within the knee joint without having to remove the device to reload a suture, a common shortcoming among other systems. More than 100,000 patients each year experience a common yet debilitating type of meniscal injury known as a meniscal root tear1. The availability of the 0 suture cartridge to the NovoStitch Pro system offers greater flexibility to physicians performing meniscal root and other complex repairs. “The considerable strain placed on the knee’s meniscus during common physical activities makes it particularly prone to injury,” said Dr. David Flanigan, professor of orthopaedics and director of the Cartilage Restoration Program at The Ohio State University Wexner Medical Center. “Having access to a larger suture provides additional possibilities for meniscal repair.” “Ceterix continues to bring advanced technology to orthopaedic surgeons who are looking for better ways to preserve the meniscus,” said John McCutcheon, Ceterix’s president and CEO. “This latest innovation will be especially beneficial to those surgeons who prefer an ‘all-inside, all-suture’ procedure with a stronger suture for the more-demanding meniscal root repairs.” The meniscus is a crescent of soft cartilage that sits between the femur and tibia, providing stability and shock absorption to the knee. The meniscus attaches to the tibia at its root but is subject to tearing at this attachment point. Historically, this type of repair would have been treated with a meniscectomy (complete or partial removal of the meniscus) which has been shown in studies to increase a patient’s risk of developing osteoarthritis, which may lead to total knee replacement later in life.2 Arthroscopic surgery is a minimally-invasive procedure in which an orthopaedic surgeon treats a damaged joint through small incisions using specialized tools guided by a tiny camera called an arthroscope. Meniscus surgery is the most common arthroscopic procedure in the United States, with roughly one million performed annually.3,4 About Ceterix® Orthopaedics Ceterix Orthopaedics develops surgical tools that fill unmet clinical needs for physicians who treat soft tissue joint injuries such as meniscus tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel meniscal repair system enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all. The NovoStitch Pro Meniscal Repair System has received 510(k) clearance in the United States and is indicated for approximation of soft tissue in meniscal repair procedures. The company is based in Fremont, Calif., and is backed by investors Versant Ventures, 5AM Ventures, and CRG. For more information, please visit www.ceterix.com and follow us at @ceterix on Twitter. 1Cinque, M. E., Chahla, J., Moatshe, G., Faucett, S. C., Krych, A. J., & LaPrade, R. F. (2018, July 01). Meniscal root tears: A silent epidemic. http://dx.doi.org/10.1136/bjsports-2017-098942 2Chung et.al. Arth 2015 Oct; 31(10):1941-50. 3Brinker MR, O’Connor DP, Pierce P, Woods GW, Elliott MN. Utilization of orthopaedic services in a capitated population. J Bone Joint Surg Am. 2002 Nov; 84-A (11):1926-32. 4New Hampshire Outpatient Surgery: Knee arthroscopy data. Vol. 2008. New Hampshire Comprehensive Health Care System; 2006.

Contacts

for Ceterix Orthopaedics, Inc. Durae Hardy Durae@healthandcommerce.com

Read More
28 Aug

SpinalCyte, LLC Announces New U.S. Patent

August 28, 2018

HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts, today announced issuance of U.S. Patent No. 10,052,410, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent involves an in vivobioreactor which acts as a delivery system to feed and grow cells, like fibroblasts, and induces cellular differentiation. Additionally, the device will also be subject to one or more growth factors which may enhance differentiation of the cells. “Our patent portfolio uniquely positions us at the forefront of human dermal fibroblast cell therapy for spinal disc regeneration,” said Pete O’Heeron, Chief Executive Officer, SpinalCyte. “As leaders in this field, we continue to expand our intellectual property protections.” With this addition, SpinalCyte’s portfolio now includes 33 U.S. and foreign patents issued and 43 patents pending. About SpinalCyte Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine company developing an innovative solution for spinal disc regeneration using human dermal fibroblasts. Currently, SpinalCyte holds 33 U.S. and international issued patents and has filed for an additional 43 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.

Contacts

Russo Partners LLC for SpinalCyte, LLC David Schull, 858-717-2310 david.schull@russopartnersllc.com or Ned Berkowitz, 646-942-5629 ned.berkowitz@russopartnersllc.com

Read More
27 Aug

Medicrea to Begin Trading on the OTCQX Market in the U.S.

August 27, 2018

LYON, France & NEW YORK--(BUSINESS WIRE)--The Medicrea Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the transformation of spinal surgeries through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD ASI™ technologies, announced today that the Company will begin trading on the OTCQX Best Market under the tickers “MRNTY” and “MRNTF” on Tuesday, the 28th of August, 2018. “Being qualified to trade on the OTCQX Best Market in the U.S. is a great opportunity for Medicrea as well as for institutional and individual investors looking for a transformational medical device company. We believe that our proprietary patient-specific UNiD ASI™ (Adaptive Spine Intelligence) technology will become standard of care across the spine industry over the coming years and that it will replace the current approach, which requires manual implant manipulation and selection from a limited range that is not tailored to individual patients or surgeons,” stated Denys Sournac, Chief Executive Officer of Medicrea. “The U.S. is an important market for Medicrea’s UNiD ASI™ platform as it represents the largest global market for spinal surgery and represents a key growth area with the Company’s largest subsidiary based in New York City. As we continue to drive Medicrea’s technology adoption in the U.S., we want U.S. investors to have a simple and efficient way to invest in Medicrea. Joining OTCQX will complement our European listing on EURONEXT Growth – Paris, providing additional opportunities for liquidity to the global investment community,” expanded Mr. Sournac. The Company will trade under two separate tickers, MRNTY, which will represent the Company’s American Depository Receipts (“ADR”) and MRNTF, which will represent the Company’s ordinary shares. Each ADR represents one share of the Company’s ordinary shares. Investors will have the opportunity to purchase in dollars either ADR or ordinary shares. "We are excited to welcome Medicrea to the OTCQX Best Market," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Trading on the OTCQX Market will give Medicrea the opportunity to increase visibility within the U.S. and grow its investor base. Historically, international companies who trade on OTCQX have both increased the number of U.S.-based investors and improved trading volume in their home market, providing a benefit for investors in the U.S. and in their domestic markets." About Medicrea (www.medicrea.com) Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room. Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 200 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants. For further information, please visit: Medicrea.com. About OTC Markets Group Inc. OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, OTC Markets Group connects a diverse network of broker-dealers that provide liquidity and execution services. OTC Markets Group enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

Connect with Medicrea: FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on EURONEXT Growth Paris ISIN: FR 0004178572 Ticker: ALMED LEI: 969500BR1CPTYMTJBA37

Medicrea is traded on OTCQX Best Market Symbol: MNRTY & MRNTF

Contacts

Medicrea Denys Sournac Founder, Chairman and CEO dsournac@Medicrea.com or Fabrice Kilfiger, +33 (0)4 72 01 87 87 Chief Financial Officer fkilfiger@Medicrea.com

Read More